RESOMER L 210 S is a medical-grade poly(L-lactide) homopolymer manufactured by Evonik Industries AG and supplied as a high-inherent-viscosity resin for bioresorbable implant and device fabrication. The grade belongs to the RESOMER L series, in which the L designation refers to the L-lactide stereoisomer and the numeric suffix positions the product in the higher-molecular-weight range of the series. Supplier-published typical values list an inherent viscosity of 3.8 dL/g measured at 0.1% (w/v) in chloroform at 25 °C with an Ubbelohde capillary viscometer, following the dilute-solution viscosity principles of ASTM D2857-95(2007). Differential scanning calorimetry under ASTM D3418-15 identifies a glass transition temperature of 60–65 °C and a principal melting endotherm at 180–185 °C. The resin is semicrystalline in its thermodynamically stable state, but fabricated articles can be quenched to an amorphous condition with a melting enthalpy below 10 J/g; annealing at 100–120 °C for 2–4 h raises the measured melting enthalpy above 30 J/g. Supplier-controlled limits for residual monomer and residual solvent are below 0.5 wt% and 0.1 wt%, respectively. The product is sold as a granulate or pellet, not as a finished implant.

The medical-grade designation is a manufacturing-input classification rather than a device-level approval. The supplier's polymer production is supported by a quality management system certified to ISO 13485:2016, and batch-release documentation typically includes inherent viscosity, residual monomer, residual solvent, and residual metals. A device manufacturer using RESOMER L 210 S must still perform a biological evaluation under ISO 10993-1:2018, demonstrate compliance with ASTM F1925-22 for semi-crystalline poly(L-lactide) surgical implant resins, and generate finished-device data according to the intended anatomical site and load. Regulatory master-file access may be available to support submissions, but the polymer itself is not an FDA-cleared or CE-marked medical device.

How does a 3.8 dL/g inherent viscosity constrain drying, extrusion, and injection-molding?

The processing window is defined by two simultaneous demands: the melt temperature must be high enough to reduce viscosity for shaping, but moisture and residence time must remain low enough to prevent hydrolytic and thermal chain scission. Pre-drying is mandatory before any melt process. A vacuum oven or dehumidifying hopper at 70–80 °C for 4–8 h is used, with a tray-bed depth below 5 cm to avoid diffusion-limited moisture release. The target moisture is below 250 ppm (0.025 wt%), measured by Karl Fischer titration under ISO 15512:2019. At melt temperatures of 180–200 °C, water concentrations above this threshold can produce a measurable reduction in molecular weight during a single pass; published PLLA hydrolysis studies report chain scission of 10–20% at 0.02 wt% moisture under typical residence times, although the exact value depends on equipment and screw design. Degradation is autocatalytic because carboxylic acid end groups formed by ester hydrolysis lower the local pH and accelerate further chain scission.

On a co-rotating twin-screw extruder with L/D 30:1 and screw diameter of 19 mm, barrel profiles are ordinarily set from 170 °C at the feed throat to 195 °C at the die, with screw speed limited to 100–200 rpm. Capillary rheometry on PLLA homopolymers at 180–200 °C gives a power-law index of 0.5–0.7 over 50–500 s⁻¹; the high viscosity produces significant viscous dissipation, so screw-speed increases above 200 rpm can raise melt temperature beyond the set-point and accelerate degradation. For pelletizing, a strand water bath at 35–50 °C and cooling length of 1.0–1.5 m are commonly required to reduce tack in amorphous strands. Screen packs of 60/100/60 mesh may be used for contamination control, but pressure at the breaker plate should not exceed 150 bar for this viscosity class.

Injection molding of high-IV PLLA uses a melt-temperature window of 185–205 °C and mold temperatures of 25–40 °C for amorphous parts or above 100 °C for semicrystalline parts. Screw back pressure is typically held at 10–20 bar, and screw surface speed is kept below 0.1 m/s to reduce shear heating. If a cold mold is used, the resulting amorphous part can be annealed at 100–120 °C for 2–4 h to develop crystallinity; however, crystallization raises modulus while reducing fracture strain, and this trade-off must be evaluated on finished devices under ASTM F2502-17 for bioabsorbable fixation hardware. Mold-filling simulation for this grade requires measured Cross-WLF viscosity data; supplier-published Cross-WLF coefficients for RESOMER L 210 S are not routinely provided in public technical literature, so rotary or capillary rheometry is necessary before tool steel is cut.

Load-bearing bioresorbable fixation devices are the primary application class for RESOMER L 210 S. Injection-molded or machined components made from high-IV PLLA of this type exhibit tensile strengths in the 60–70 MPa range and tensile moduli near 3.0 GPa when tested according to ASTM D638-14. In vitro degradation under ASTM F1635-16 in phosphate-buffered saline at 37 °C typically shows tensile-strength retention during the first 6 months and measurable loss between 6 months and 12 months; substantial mass loss is not observed before 24 months in many published configurations. Published data for this specific grade in every implant geometry and loading condition is limited, so device-level degradation must be established on finished products with the intended buffer replacement schedule, pH, and mechanical load.

Within the RESOMER L series, lower-suffix grades such as RESOMER L 207 S possess a supplier-published inherent viscosity near 1.5–2.0 dL/g and are used for melt-spun fibers, coatings, or drug-delivery matrices in which higher flow and faster degradation are acceptable. Compared with those grades, RESOMER L 210 S produces higher melt pressure, higher initial tensile strength, and longer mass-loss time. The relationship between inherent viscosity and degradation rate is not linear: crystallinity, acid-end-group concentration, and sample geometry all influence the hydrolytic path. Comparative degradation must therefore be performed under ASTM F1635-16 on samples of identical thickness and processing history, not inferred from dilute-solution viscosity alone.

Poly(L-lactide-co-glycolide) 85:15 is an amorphous copolymer with a glass transition near 50–55 °C and no melting endotherm; it undergoes in vitro mass loss in 3–6 months under PBS at 37 °C. RESOMER L 210 S is semicrystalline, melts near 180–185 °C, and retains mass beyond 24 months under the same conditions. For solvent-based microsphere or nanoparticle fabrication, the high solution viscosity of RESOMER L 210 S at equivalent concentration is a process disadvantage relative to lower-IV PLGA or lower-IV PLLA grades, because organic-phase viscosities above 200 mPa·s hinder droplet breakup during high-shear dispersion and broaden the particle-size distribution. PLGA or low-IV PLLA grades are therefore preferred for drug-delivery depots requiring short- to medium-term release, whereas the high-IV homopolymer is selected for load-bearing structural implants.

Selection Boundaries Between Semicrystalline PLLA and Amorphous PLGA

The choice of RESOMER L 210 S over an amorphous PLGA copolymer is technically justified when the device must maintain mechanical competence for several months and can tolerate a hydrolytic degradation tail extending beyond 24 months. In PLLA, water uptake and hydrolysis are initially confined to the amorphous interlamellar regions; the crystalline lamellae reduce water diffusion and act as physical crosslinks, preserving modulus and mass. This produces a two-stage profile: molecular weight falls before gross mass loss occurs. Under ASTM F1635-16, an amorphous PLGA 85:15 of comparable initial molecular weight can lose mechanical integrity within 2–3 months, depending on geometry and buffer exchange, whereas high-IV PLLA is expected to maintain some strength at 6 months. The residual crystalline fraction, however, can generate acid-rich degradation products and a late-stage inflammatory response if large implants are used; the device manufacturer must evaluate local pH under ISO 10993-6:2016 implantation studies.

Compounding RESOMER L 210 S with osteoconductive fillers such as β-tricalcium phosphate or hydroxyapatite is possible but adds another processing boundary. On a 32:1 L/D twin-screw compounder, fillers are preferably fed through a downstream side-stuffer after the polymer is melted at 185–195 °C; simultaneous feed of filler and high-IV PLLA can create excessive initial torque and reduce molecular weight. Final filler dispersion must be verified by scanning electron microscopy or microcomputed tomography because agglomerates larger than 50 µm can act as stress concentrators and reduce tensile strength below the 60 MPa range observed for the neat polymer. Filler loadings above 30 wt% may require plasticizers or processing aids, but these additives can alter degradation kinetics and must be reviewed under ISO 10993-1:2018.

The property balance is also affected by solid-state orientation. Uniaxial drawing of quenched PLLA sheets at 70–90 °C to draw ratios of 3:1 to 4:1 can increase tensile strength to above 100 MPa along the draw direction; however, published data for RESOMER L 210 S in drawn fiber or film configurations is limited, and such process development requires measured stretching force and crystallization onset. In oriented forms, the release of oriented amorphous chains during heating leads to shrinkage unless annealing at 100–120 °C is performed. These processing routes are relevant for bioresorbable stents and suture reinforcements but require more extensive validation than injection-molded parts.

Because PLLA is synthesized by ring-opening polymerization of L-lactide in the presence of a tin-based catalyst, residual tin levels are relevant to toxicological assessment. Supplier batch-release documentation for medical-grade PLLA typically reports residual tin below 100 ppm; final device biocompatibility must nevertheless be established by extractables and leachables testing under ISO 10993-18:2020. The high melt viscosity of RESOMER L 210 S may also require processing temperatures close to the upper limit of the supplier's recommended range; excursions above 230 °C should be avoided because thermal degradation can generate lactide monomer and color bodies that alter both mechanical properties and regulatory compliance.

Terminal sterilization imposes a further operational boundary. Gamma irradiation at 25–40 kGy is known to cause chain scission in poly(L-lactide) and can increase carboxylic acid end groups; if gamma sterilization is required, the minimum dose to achieve sterility under ISO 11137-2:2013 should be selected, and post-irradiation inherent viscosity should be measured. Ethylene oxide sterilization at chamber temperatures below 50 °C is generally preferred for high-molecular-weight PLLA because it avoids ionizing-radiation chain scission, but residual ethylene oxide and ethylene chlorhydrin must be controlled under ISO 10993-7:2008. Packaging for ethylene oxide must have a low water-vapor transmission rate to prevent humidification of the PLLA during the humidification and aeration phases. Unopened containers are stored at −20 °C in sealed, desiccant-lined foil bags. Containers must be equilibrated to room temperature before opening to prevent surface condensation, and any unused resin must be redried to below 250 ppm moisture before reuse.